AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 51 min read$TWST

Cho Dennis sold $91K of TWST

Cho Dennis (See Remarks) sold 1,070 shares of Twist Bioscience Corp (TWST) at $85.32 on 2026-08-03.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed open-market sale may modestly influence short-term sentiment, but it does not provide new operational, financial, or regulatory information about TWST.

02

Market read

A routine insider sale is disclosed, offering limited incremental trading signal absent other company-specific catalysts.

03

What to watch

The article does not state the insider’s total compensation, tax obligations, or whether other sales occurred around the same time; absence of a cited 10b5-1 plan may increase speculation but is not proof of information advantage.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Cho Dennis filed a Form 4 selling 1,070 shares at $85.3212 on 2026-08-03, totaling $91,293.68.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing discloses a single insider sale size and price, but provides no new company fundamentals, guidance, or legal/operational developments.

Market effects

Sector

Minimal; insider sale does not change biotech/genomics sector fundamentals in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification and do not necessarily signal reduced confidence, especially when the company has no accompanying negative news in the filing.

Key entities

  • issuer
    Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Cho Dennis

    Officer who sold 1,070 shares at $85.3212 on 2026-08-03.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min